Logo image
MP24-14 PEMBROLIZUMAB (PEMBRO) PLUS OLAPARIB IN PATIENTS WITH DOCETAXEL-PRETREATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC): UPDATED RESULTS FROM KEYNOTE-365 COHORT A WITH A MINIMUM OF 11 MONTHS OF FOLLOW-UP FOR ALL PATIENTS
Journal article   Peer reviewed

MP24-14 PEMBROLIZUMAB (PEMBRO) PLUS OLAPARIB IN PATIENTS WITH DOCETAXEL-PRETREATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC): UPDATED RESULTS FROM KEYNOTE-365 COHORT A WITH A MINIMUM OF 11 MONTHS OF FOLLOW-UP FOR ALL PATIENTS

Luke T. Nordquist, Evan Y. Yu, Josep M. Piulats, Gwenaelle Gravis, Peter C.C. Fong, Tilman Todenhoefer, Brigitte Laguerre, Jose Angel Arranz Arija, Stephane Oudard, Christophe Massard, …
The Journal of urology, Vol.206(Supplement 3), pp.e417-e417
09/2021
url
https://doi.org/10.1097/JU.0000000000002015.14View
Published (Version of record) Open

Metrics

1 Record Views

Details

Logo image